All News

Swedish population study of psoriasis pts Rx w/ secukinumab (848) or ustekinumab (1107) showed slightly more respiratory infx & UTI (HR 1.22), w/ no difference in hospital treated severe respiratory, UTI (HR 0.96) or candidiasis (HR 1.80) https://t.co/yIRubED6VX

Links:

https://bit.ly/3iwXi1l

Dr. John Cush RheumNow ( View Tweet)

Oct 06, 2020

Meta-analysis shows smoking increases the risk of psoriasis (OR: 1.84) in the general population, but smoking the risk of PsA among psoriasis patients (OR: 0.70) but was equal to the general populatoin. https://t.co/4MkpkFQlqr

Links:

https://bit.ly/2Si7LCW

Dr. John Cush RheumNow ( View Tweet)

Oct 01, 2020

The RheumNow Podcast is up! Cardiovascular Risk in Psoriatic Disease, Higher COVID rates in young adults, Reimbursements for Rheumatologists and more. Watch here>> https://t.co/cBHTeUQhff or liste to podcast here> https://t.co/KBgmsoGRzU or on iTunes> https://t.co/FHJv01AAbC

Links:

https://bit.ly/2S3jm8V

Dr. John Cush RheumNow ( View Tweet)

Sep 27, 2020

Links:

https://bit.ly/3j0LtBq

Dr. John Cush RheumNow ( View Tweet)

Sep 27, 2020

Links:

https://bit.ly/2WXXRIy

Dr. John Cush RheumNow ( View Tweet)

Sep 27, 2020

High-risk coronary plaques (LRNC) assessed by Coronary CT scores in 209 biologic naive Psoriasis pts. LNRC correlated w/ Framingham risk & Dz activity. After 1 year those on biologics had signif reduction in LRNC, but those not on biologics had no change https://t.co/8o74pjIs5n

Links:

https://bit.ly/2G0PY0x

Dr. John Cush RheumNow ( View Tweet)

Sep 25, 2020

Romilkimab Effective in Early Diffuse Systemic Sclerosis

Save

d Jack Cush, MD

Sep 24, 2020

A phase II study of patients with early diffuse systemic sclerosis (SSc) has demonstrated improvement in SSc skin outcomes by targeting T cells and fibrosis with the bispecific monoclonal antibody romilkimab (RMK).

Read Article

The EMAs Committee for Medicinal Products for Human Use (CHMP) has recommended baricitinib for approval in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy https://t.co/goEacN1C8X

Links:

https://wb.md/33UAdjD

Dr. John Cush RheumNow ( View Tweet)

Sep 23, 2020

Updated List of Drugs Inducing Lupus

Save

d Jack Cush, MD

Sep 14, 2020

Drugs inducing lupus may account for nearly 30% of all subacute cutaneous lupus erythematosus (CLE) and up to 15% of systemic lupus erythematosus (SLE) cases. Moreover there are over 100 drugs capable of inducing drug-induced lupus erythematosus.

Read Article

Comorbidities Impact Disease Activity in Spondyloarthritis

Save

d Jack Cush, MD

Sep 13, 2020

An analysis of a large population-based cohort of axial spondyloarthritis (axSpA) patients shows that comorbidities are common and are associated with higher disease activity and higher levels of functional impairment.

Read Article

Study of 211 SSc pts (70% with limited SSc) & during 120 (50-216) mos F/U, 105 (50%) had 1 or more skin ulcer (SU); 66% recurrent/persistent SUs. Being younger at Dx, articular involvement and telangiectasia were independently associated with SUs https://t.co/yLurnaft5X

Links:

https://bit.ly/34SvP75

Dr. John Cush RheumNow ( View Tweet)

Sep 02, 2020

Successful treatment of refractory palmoplantar psoriasis in a psoriatic arthritis patient with the JAK inhibitor tofacitinib https://t.co/bdhppoUkmz

Links:

https://bit.ly/3guYQYy

Dr. John Cush RheumNow ( View Tweet)

Aug 26, 2020

RheumNow Podcast – The Bad News That’s Fit to Print (8.21.20)

Save

d Jack Cush, MD

Aug 20, 2020

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow: filgotinib rejection, delays in diagnosis, metformin benefits COVID, Abx and IBD, and UPA beats MTX.

Read Article

New Criteria for Discoid Lupus

Save

d Jack Cush, MD

Aug 19, 2020

JAMA Dermatology has proposed an initial validation of classification criteria for discoid lupus erythematosus (DLE), primarily for research purposes, but with clinical applicatility.

Read Article

Hong Kong study Myositis-specific autoantibodies in 201 pts with idiopathic inflammatory myopathies (IIM) shows MDA-5 (14%), TIFF-1γ (14%), Jo-(12.4%). MDA5 seen w/ DM, digital ulcers, amyopathy, ILD. TIF1γ was associ w/ refractory rash and cancer https://t.co/3E365F5SON

Links:

https://bit.ly/2PtU9TU

Dr. John Cush RheumNow ( View Tweet)

Aug 07, 2020

Virtual Video Joint Exam Pearl #5: Its easier to see gouty Tophi and rheumatoid nodules than nail changes of PsA or subtle rashes. For Rashes and oral lesions its BEST to have the patient take multiple pix with the cell phone and send them in by EMR or Email.

Dr. John Cush RheumNow ( View Tweet)

Aug 04, 2020

Lenabasum (cannabinoid rcptr agonist) studied in Systemic Sclerosis - LEN (n=27) vs PBO (n=15). At wk 16 LEN had better responses by CRISS (skin) score (0.33, vs 0; P=0.07) w/ reduced gene expression for inflammation & fibrosis & improved skin histology https://t.co/oddSMvjnc9 https://t.co/HLFPNfigFD

Links:

https://bit.ly/32TCgG1

Dr. John Cush RheumNow ( View Tweet)

Jul 29, 2020

The RheumNow Podcast is up - COVID-19 Responds to Steroids & TCZ, statin myopathy, Lung Dz in AOSD, TNFi & Liver, IL-23 in Psoriasis. Watch it here>> https://t.co/DrrFZSWmZa or listen to Podcast on iTunes>> https://t.co/FHJv01AAbC or on SoundCloud>> https://t.co/nSPI9lcaY9

Links: